hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia & Hyperphosphatemia Drug Information

Drug Information
Cebion Vitamin C + Calcium Effervescent Tablet
ascorbic acid + calcium carbonate

Indication: Health supplement.

Indication: Severe hypophosphataemia (serum levels <0.3 mmol/L) & other degrees of hypophosphataemia when oral ther...

Indication: Phosphate-binding agent for control of hyperphosphataemia in chronic renal failure patients on haemodialysis o...

Ca-C 1000 Sandoz
ascorbic acid + calcium carbonate + calcium lactat...
Calcium Vitamin D3 Stada
calcium carbonate + calcium lactate gluconate + co...
Calcium with Vitamin D Plus YSP
calcium carbonate + vitamin D
Calcium-Sandoz 600 + Vitamin D3
calcium carbonate + calcium lactate gluconate + co...
1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 5 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.